Genome Research Institute; National Center for Research Resources; and National Center for Complementary and Alternative Medicine.

The purpose of the working meeting is to discuss the current status of drug research in neonates and pre-term infants. The meeting will focus on exploring gaps in existing knowledge in this field and in developing strategies to rectify the gaps that could be implemented by federal agencies and the scientific community.

Participants at the meeting will develop recommendations for potential research approaches for current and future pharmaceutical agents for use in newborns. The focus will be on issues related to: Trial design, ethics, pharmacokinetics, pharmacodynamics, efficacy and toxicity, drug formulations, drug prioritization, and surveillance of adverse events. Additional discussion will consider the assessment of long term outcomes and issues related to research in small subpopulations.

Attendance at the meeting will be limited. Persons interested in attending the meeting should submit a request containing the following information to

Name Address Telephone Fax E-mail

Persons interested in obtaining more information about the meeting may contact Dr. Donald Mattison, NICHD, 6100 Executive Boulevard, Room 4B–100, Rockville, MD 20892, e-mail kestpharmaceuticals@mail.nih.gov, telephone 301–496–5097 (not a toll-free number).

Dated: September 12, 2003.

Raynard Kington,

Deputy Director, National Institutes of Health. [FR Doc. 03–23904 Filed 9–18–03; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Fogarty International Center; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Fogarty International Center Advisory Board, September 16, 2003, 8:30 a.m. to September 16, 2003, 5 p.m., National Institutes of Health, Lawton Chiles International House, Bethesda, MD, 20892 which was published in the **Federal Register** on September 9, 2003, 68 FR 174. The meeting will be held at the Natcher Bldg. Room E1–E2 45 Center Dr., Bethesda, MD 20892. The meeting is partially Closed to the public.

Dated: September 11, 2003.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 03-23899 Filed 9-18-03; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel, Urine Sediment DNA: Reproductive Status and Health Index.

Date: October 14, 2003.

Time: 3:30 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6100 Executive Boulevard, 5B01, Rockville, MD 20852, (telephone conference Call).

Contact Person: Jon R. Ranhand, PhD, Scientist Review Administrator, Division of Scientific Review, National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5E03, Bethesda, MD 20892, (301) 435–6884.

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: September 11, 2003.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 03–23895 Filed 9–18–03; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel, Analysis of Cell Cycle Checkpoints in Human Oocytes.

Date: October 16, 2003. Time: 10 a.m. to 12 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6100 Executive Boulevard, 5B01, Rockville, MD 20852 (Telephone Conference call).

Contact Person: Jon M. Ranhand, Ph.D., Scientist Review Administrator, Division of Scientific Review, National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5E03, Bethesda, MD 20892, (301) 435–6884.

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health. HHS)

Dated: September 11, 2003.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 03–23896 Filed 9–18–03; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice